Welcome to our dedicated page for Bausch + Lomb news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb stock.
Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Bausch + Lomb (NYSE:BLCO) announced the U.S. launch of Blink Triple Care Preservative Free lubricant eye drops, a multi-dose, preservative-free version of the existing Blink Triple Care formula.
The lipid- and water-based drops use a natural oil and hyaluronate to create a dual-action moisture seal, offering 3‑in‑1 extended relief and up to 10 hours of dry eye symptom relief. The product is expected to be available at most major U.S. retailers and online, including Amazon, CVS, Target and Walgreens, by the end of June 2026.
Bausch + Lomb (NYSE:BLCO) announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of R&D Yehia Hashad will join a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 9, 2026, at 1:20 p.m. ET. A live webcast will be accessible via the company’s investor relations website.
Bausch + Lomb (NYSE/TSX: BLCO) reported results of its 2026 annual meeting of shareholders held May 20, 2026. Shareholders elected 10 nominated directors, with each receiving over 331 million votes in favor and about 4.2–4.3 million against, plus broker non-votes.
Shareholders also approved, on a non-binding advisory basis, the compensation of named executive officers and appointed PricewaterhouseCoopers LLP as independent registered public accounting firm until the close of the 2027 annual meeting. Final vote tabulations will be filed on Form 8-K and posted on SEDAR+ and the company website.
Bausch + Lomb (NYSE:BLCO) launched PreserVision AREDS3 eye vitamins in the U.S. The formula combines clinically proven AREDS2 nutrients recommended by the NEI with a unique B‑vitamin complex to support macular health and help reduce the risk of moderate‑to‑advanced AMD progression.*
The triple‑action formula is designed to protect, nourish and boost macular health and is now available at most major retailers nationwide.
Bausch + Lomb (NYSE: BLCO) launched the Bi-Blade+ dual-port vitrectomy cutter in Europe for use with the Stellaris Elite vision enhancement system on May 7, 2026. Bi-Blade+ offers a 25,000 cpm cutting speed and a reported 25% average flow increase versus Bi-Blade, with a 62% reduction in cutter vibration and a 62% reduction in average infusion pressure when used with Adaptive Fluidics. The device is indicated for anterior and posterior vitrectomy, is compatible only with Stellaris Elite systems having Bi-Blade+ procedure pack compatibility, and includes standard surgical risks; users should consult Instructions for Use for full safety details.
Bausch + Lomb (NYSE: BLCO) announced a second R&D “Teach-in” webinar on June 1, 2026 at 1:00 p.m. ET featuring senior R&D leaders.
Speakers will discuss two contact lens programs: a bioactive lens using polymerized hyaluronic acid (first new lens material in >25 years) and a silicone hydrogel daily lens targeting myopia progression. CEO Brent Saunders and CFO Sam Eldessouky will participate. The live session is hosted by Citi; a replay will be posted on the company Investor Relations page.
Bausch + Lomb (NYSE: BLCO) will present more than 40 scientific studies at the ARVO Annual Meeting in Denver, CO, May 3-7, 2026. Presentations cover marketed products (Xiidra, MIEBO, enVista Envy, Biotrue, INFUSE/ULTRA ONE DAY) and pipeline programs in glaucoma, AMD, neuropathic pain, and extended‑depth‑of‑focus IOLs.
Topics include clinical outcomes, contact lens care, IOL optics, dry eye treatments, antimicrobial disinfection, and preclinical/translational data for investigational candidates.
Bausch + Lomb (NYSE: BLCO) reported Q1 2026 revenue of $1.244 billion, up 9% reported and ~6% at constant currency, with GAAP net loss attributable of $71 million and adjusted EBITDA excluding acquired IPR&D of $200 million. The company raised full‑year 2026 guidance to $5.420B–$5.520B revenue and $1.010B–$1.060B adjusted EBITDA excluding acquired IPR&D.
Segment growth came from Vision Care, Surgical, and Pharmaceuticals, driven by dry eye products, premium IOLs, SiHy daily lenses and stronger MIEBO and XIIDRA sales.
Bausch + Lomb (NYSE: BLCO) published a narrative review linking certain B vitamins to lower risk and slower progression of age-related macular degeneration (AMD), synthesizing >20 human studies and ~30,000 participants. The company launched PreserVision AREDS3 with a B‑vitamin complex, available in the U.S. and rolling out to major retailers by June 2026, and is planning a long-term clinical trial to evaluate the new formulation.
Bausch + Lomb (NYSE: BLCO) released its 2025 Sustainability Impact Report and introduced The Broader Perspective framework to guide environmental, social and governance action. The report reaffirms a Net Zero by 2050 commitment and lists 2025 accomplishments in energy, waste reduction, supplier risk registration and community programs.